B-cell lymphoma-2 family proteins in the crosshairs: Small molecule inhibitors and activators for cancer therapy.

Gong, Qineng; Wang, Haojie; Zhou, Mi; Zhou, Lu; Wang, Renxiao; Li, Yan

Gong, Qineng; Wang, Haojie; Zhou, Mi; Zhou, Lu; Wang, Renxiao; Li, Yan.

Affiliation

Gong Q; Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.
Wang H; Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.
Zhou M; Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.
Zhou L; Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.
Wang R; Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.
Li Y; Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.

Med Res Rev ; 44(2): 707-737, 2024 Mar.

Article in En | MEDLINE | ID: mdl-37983840

Subject(s)

Neoplasms; Proto-Oncogene Proteins; Humans; Proto-Oncogene Proteins/metabolism; Proto-Oncogene Proteins/pharmacology; bcl-2 Homologous Antagonist-Killer Protein/genetics; bcl-2 Homologous Antagonist-Killer Protein/metabolism; bcl-2 Homologous Antagonist-Killer Protein/pharmacology; bcl-2-Associated X Protein/genetics; bcl-2-Associated X Protein/metabolism; bcl-2-Associated X Protein/pharmacology; Proto-Oncogene Proteins c-bcl-2/metabolism; Apoptosis; Neoplasms/drug therapy

Key words

BCL-2 family proteins; antiapoptotic; cancer therapy; proapoptotic; structure-based drug design

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proto-Oncogene Proteins / Neoplasms Limits: Humans Language: En Journal: Med Res Rev Year: 2024 Type: Article

Fulltext

XML

PubMed Links

Search on Google